Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges.
The combination of radiation therapy and immunotherapy holds particular promise as a strategy for cancer therapeutics. Evidence suggests that immunotherapy is most beneficial alone when employed early in the disease process or in combination with standard therapies (eg, radiation) later in the disease process. Indeed, radiation may act synergistically with immunotherapy to enhance immune responses, inhibit immunosuppression, and/or alter the phenotype of tumor cells, thus rendering them more susceptible to immune-mediated killing. As monotherapies, both immunotherapy and radiation may be insufficient to eliminate tumor masses. However, following immunization with a cancer vaccine, the destruction of even a small percentage of tumor cells by radiation could result in crosspriming and presentation of tumor antigens to the immune system, thereby potentiating antitumor responses. Learning how to exploit radiation-induced changes to tumor-cell antigens, and how to induce effective immune responses to these cumulatively immunogenic stimuli, is an exciting frontier in cancer therapy research. This review examines mechanisms by which many forms of radiation therapy can induce or augment antitumor immune responses as well as preclinical systems demonstrating that immunotherapy can be effectively combined with radiation therapy. Finally, we review current clinical trials where standard-of-care radiation therapy is being combined with immunotherapy.
Hodge
James W
JW
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Guha
Chandan
C
Neefjes
Jacques
J
Gulley
James L
JL
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000276:immunology* / Q000532:radiotherapy*; D011839:Radiation, Ionizing; D011878:Radiotherapy / Q000379:methods*; D018714:Radiotherapy, Adjuvant
D000911:Antibodies, Monoclonal
Cell Death Differ. 2008 Jan;15(1):3-12
18007663
Nat Med. 1998 May;4(5):581-7
9585232
Cell Immunol. 1995 Oct 15;165(2):243-51
7553889
Nat Med. 2007 Sep;13(9):1050-9
17704786
J Clin Oncol. 2000 Dec 1;18(23):3964-73
11099326
Clin Cancer Res. 2008 Aug 15;14(16):5284-91
18698048
J Exp Med. 2005 Oct 3;202(7):907-12
16203864
Nat Med. 2007 Jan;13(1):54-61
17187072
Clin Cancer Res. 2007 Mar 1;13(5):1493-502
17332294
J Immunother. 2005 Mar-Apr;28(2):129-35
15725956
J Nucl Med. 1993 Jul;34(7):1031-6
7686217
Clin Cancer Res. 2008 Jul 1;14(13):4241-9
18594006
J Natl Cancer Inst. 1995 Feb 15;87(4):280-5
7707419
J Immunol. 1998 Aug 1;161(3):1083-6
9686565
Int Immunol. 2000 Nov;12(11):1539-46
11058573
Trends Immunol. 2005 Feb;26(2):111-7
15668127
J Immunol. 2002 Oct 1;169(7):3760-70
12244170
J Immunother. 2000 Sep-Oct;23(5):570-80
11001550
Radiat Res. 2006 Dec;166(6):819-31
17149971
Clin Cancer Res. 2005 May 1;11(9):3353-62
15867235
Immunity. 2001 Mar;14(3):303-13
11290339
Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S171-8
15127241
Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):655-66
16199306
Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):767-77
10837963
Radiother Oncol. 1999 Feb;50(2):199-204
10368044
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862-70
14967443
Int J Radiat Biol. 2007 Nov-Dec;83(11-12):819-25
17852561
Pharmacol Ther. 1999 Apr;82(1):97-106
10341360
Cancer Res. 2004 Nov 1;64(21):7985-94
15520206
J Leukoc Biol. 2005 Mar;77(3):361-8
15569694
J Exp Med. 1999 Mar 1;189(5):797-802
10049943
Expert Rev Mol Med. 2000 Apr 19;2(3):1-24
14585140
Cancer Res. 2004 Jun 15;64(12):4328-37
15205348
J Immunol. 2003 Jun 15;170(12):6338-47
12794167
Oncogene. 2008 Jan 7;27(2):200-7
18176601
Int Immunopharmacol. 2003 Aug;3(8):1093-1104
12860166
Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5280-9
17875756
J Exp Med. 2006 May 15;203(5):1259-71
16636135
Eur J Histochem. 1994;38 Suppl 1:53-60
8547711